BR112022005472A2 - Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica - Google Patents
Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêuticaInfo
- Publication number
- BR112022005472A2 BR112022005472A2 BR112022005472A BR112022005472A BR112022005472A2 BR 112022005472 A2 BR112022005472 A2 BR 112022005472A2 BR 112022005472 A BR112022005472 A BR 112022005472A BR 112022005472 A BR112022005472 A BR 112022005472A BR 112022005472 A2 BR112022005472 A2 BR 112022005472A2
- Authority
- BR
- Brazil
- Prior art keywords
- magl
- inhibitors
- heterocyclic
- pharmaceutical composition
- manufacturing process
- Prior art date
Links
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title abstract 3
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
nibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica. a presente invenção refere-se a compostos heterocíclicos que são inibidores de monoacilclicerol lipase (magl) tendo a fórmula geral (i) em que a, l1, x, m, n e r1 a r4 são como descritos no presente documento, composições incluindo os compostos, processos de fabricação dos compostos e métodos de uso dos compostos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19199108 | 2019-09-24 | ||
PCT/EP2020/076347 WO2021058445A1 (en) | 2019-09-24 | 2020-09-22 | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005472A2 true BR112022005472A2 (pt) | 2022-06-14 |
Family
ID=68066569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005472A BR112022005472A2 (pt) | 2019-09-24 | 2020-09-22 | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210094973A1 (pt) |
EP (1) | EP4034538A1 (pt) |
JP (1) | JP2022549446A (pt) |
KR (1) | KR20220069003A (pt) |
CN (1) | CN114401968A (pt) |
AR (1) | AR120030A1 (pt) |
AU (1) | AU2020354414A1 (pt) |
BR (1) | BR112022005472A2 (pt) |
CA (1) | CA3152213A1 (pt) |
CO (1) | CO2022002000A2 (pt) |
CR (1) | CR20220118A (pt) |
IL (1) | IL289594A (pt) |
MX (1) | MX2022002711A (pt) |
PE (1) | PE20220710A1 (pt) |
TW (1) | TW202126663A (pt) |
WO (1) | WO2021058445A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
JP2023539690A (ja) | 2020-09-03 | 2023-09-15 | エフ. ホフマン-ラ ロシュ アーゲー | 複素環式化合物 |
WO2023144160A1 (en) * | 2022-01-25 | 2023-08-03 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
WO2024088922A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
KR101653473B1 (ko) * | 2012-01-06 | 2016-09-01 | 어바이드 테라퓨틱스, 인크. | 카르바메이트 화합물 및 그의 제조 및 이용 방법 |
WO2016185279A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
DK3768684T3 (da) * | 2018-03-22 | 2023-04-24 | Hoffmann La Roche | Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere |
CA3104928A1 (en) * | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
SG11202012222TA (en) * | 2018-08-13 | 2021-01-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
-
2020
- 2020-09-22 EP EP20780981.5A patent/EP4034538A1/en active Pending
- 2020-09-22 CN CN202080061840.2A patent/CN114401968A/zh active Pending
- 2020-09-22 CR CR20220118A patent/CR20220118A/es unknown
- 2020-09-22 US US17/027,976 patent/US20210094973A1/en not_active Abandoned
- 2020-09-22 AU AU2020354414A patent/AU2020354414A1/en active Pending
- 2020-09-22 JP JP2022518756A patent/JP2022549446A/ja active Pending
- 2020-09-22 MX MX2022002711A patent/MX2022002711A/es unknown
- 2020-09-22 BR BR112022005472A patent/BR112022005472A2/pt not_active Application Discontinuation
- 2020-09-22 KR KR1020227009452A patent/KR20220069003A/ko unknown
- 2020-09-22 WO PCT/EP2020/076347 patent/WO2021058445A1/en unknown
- 2020-09-22 CA CA3152213A patent/CA3152213A1/en active Pending
- 2020-09-22 AR ARP200102633A patent/AR120030A1/es unknown
- 2020-09-22 PE PE2022000299A patent/PE20220710A1/es unknown
- 2020-09-23 TW TW109132878A patent/TW202126663A/zh unknown
-
2022
- 2022-01-03 IL IL289594A patent/IL289594A/en unknown
- 2022-02-24 CO CONC2022/0002000A patent/CO2022002000A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022002000A2 (es) | 2022-04-08 |
AU2020354414A1 (en) | 2022-02-17 |
EP4034538A1 (en) | 2022-08-03 |
AR120030A1 (es) | 2022-01-26 |
CA3152213A1 (en) | 2021-04-01 |
TW202126663A (zh) | 2021-07-16 |
WO2021058445A1 (en) | 2021-04-01 |
US20210094973A1 (en) | 2021-04-01 |
CR20220118A (es) | 2022-04-20 |
JP2022549446A (ja) | 2022-11-25 |
KR20220069003A (ko) | 2022-05-26 |
IL289594A (en) | 2022-03-01 |
MX2022002711A (es) | 2022-03-22 |
PE20220710A1 (es) | 2022-05-04 |
CN114401968A (zh) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022005472A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica | |
BR112022003704A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
BR112022002375A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
BR112019003519A2 (pt) | compostos de sulfonimidoilpurinona 7-substituídos para o tratamento e profilaxia de infecção por vírus | |
CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
BR112022003982A2 (pt) | Compostos heterocíclicos | |
BR112018003595A2 (pt) | análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 | |
BR112015004113A2 (pt) | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
BR112015023397A2 (pt) | benzoxazois substituídos e métodos de uso dos mesmos | |
BR112017017349A2 (pt) | composto, composição, método para tratar um distúrbio | |
BRPI0507830A (pt) | derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
BR112021026899A2 (pt) | Compostos heterocíclicos | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BR112022022608A2 (pt) | Compostos como inibidores de bcl-2 | |
BR112023003580A2 (pt) | Compostos heterocíclicos | |
BR112022018828A2 (pt) | Derivados de benzodiazepina como gaba a gamma1 pams | |
BR112019006414A2 (pt) | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 | |
BR112015024109A2 (pt) | derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |